Hepatitis C Virus–Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment

Gabriele Pozzato, Cesare Mazzaro, Valter Gattei

Research output: Contribution to journalReview article

Abstract

Eradication of hepatitis C virus (HCV) in indolent non-Hodgkin lymphomas (NHLs), especially in marginal zone lymphomas, determines the regression of the hematologic disorder in a significant fraction of cases. Because direct antiviral agents show an excellent profile in terms of efficacy, safety, and rapid onset of action, these drugs can be used in any clinical situation and in the presence of any comorbidities. To avoid the progression of the NHL, despite HCV eradication, antiviral therapy should be provided as soon as the viral infection is discovered; before that, the chronic antigenic stimulation determines the irreversible proliferation of neoplastic B cells.

Original languageEnglish
Pages (from-to)499-515
Number of pages17
JournalClinics in Liver Disease
Volume21
Issue number3
DOIs
Publication statusPublished - Aug 1 2017

Keywords

  • Direct antiviral agents
  • Hepatitis C virus
  • Marginal zone lymphoma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Hepatitis C Virus–Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment'. Together they form a unique fingerprint.

  • Cite this